Improvement in body mass index category was associated with improved cardiometabolic measures and patient‐reported outcomes in adults with type 2 diabetes treated with tirzepatide

Figures

• 

  FIGURE 1. Proportions of tirzepatide‐treated adults with type 2 diabetes whose body mass index (BMI) category ‘improved’ or was ‘not improved’ from baseline to primary endpoint in SURPASS‐1 to ‐5. Data from tirzepatide treatment arms (5, 10, or 15 mg) were combined. N = tirzepatide‐treated participants on treatment without rescue therapy and with available body weight measurements at Week 40 (SURPASS‐1, ‐2, and ‐5) or Week 52 (SURPASS‐3 and ‐4). BMI shift categories were defined as follows: ‘improved’ = BMI category at Week 40/52 is ≥1 BMI category lower than at baseline; ‘not improved’ = combined (‘not improved: stable’ = same BMI category at baseline and at Week 40/52 and ‘not improved: worsened’ = BMI category at Week 40/52 is ≥1 BMI category higher than at baseline).

• 

  FIGURE 2. Changes from baseline to primary endpoint in A: Glycated haemoglobin (HbA1c) (%); B: Waist circumference (cm); and C: Systolic blood pressure (mmHg) among adults with type 2 diabetes receiving tirzepatide (5, 10, or 15 mg) in SURPASS‐1 to ‐5 with an ‘improved’ versus a ‘not improved’ body mass index (BMI) category. Data from tirzepatide treatment arms (5, 10, or 15 mg) were combined. †Change from baseline n = number of participants in BMI shift category at endpoint with change from baseline cardiometabolic measure data available. ‡Baseline n = number of participants in BMI shift category at endpoint with cardiometabolic measure data available at baseline. Analysis population: tirzepatide‐treated participants on treatment without rescue therapy and with available body weight measurements at Week 40 (SURPASS‐1, ‐2, and ‐5) or Week 52 (SURPASS‐3 and ‐4). BMI shift categories were defined as follows: ‘improved’ = BMI category at Week 40/52 is ≥1 BMI category lower than at baseline; BMI ‘not improved’ = combined (‘not improved: stable’ = same BMI category at baseline and at Week 40/52 and ‘not improved: worsened’ = BMI category at Week 40/52 is ≥1 BMI category higher than at…

• 

  FIGURE 3. Changes from baseline to primary endpoint in A: Ability to Perform Physical Activities of Daily Living (APPADL) total score; B: Impact of Weight on Self‐Perceptions (IW‐SP) total score across SURPASS‐1 to ‐5; and C: Impact of Weight on Quality of Life‐Lite Clinical Trials Version (IWQOL‐Lite‐CT) scores in SURPASS‐2† among pooled adults with type 2 diabetes receiving tirzepatide (5, 10, or 15 mg) with an ‘improved’ versus a ‘not improved’ body mass index (BMI) category. Data from tirzepatide treatment arms (5, 10, or 15 mg) across all SURPASS‐1 to ‐5 studies (A and B) or in SURPASS‐2 (c). †IWQOL‐Lite‐CT instrument data were collected only in the SURPASS‐2 study. ‡Change from baseline n = number of participants in BMI shift category at endpoint with change from baseline patient‐reported outcomes (PRO) score available. §Baseline n = number of participants in BMI shift category at endpoint with PRO score available at baseline. BMI shift categories were defined as follows: ‘improved’ = BMI category at Week 40/52 is ≥1 BMI category lower than at baseline; ‘not improved’ = combined (‘not improved: stable’ = same BMI category at baseline and at Week 40/52 and ‘not improved: worsened’ =…